Prevalence of HCV-HIV coinfection. newborn babies

Transcription

1 Prevalence of HCV-HIV coinfection among mothers of newborn babies Mercedes Díez Secretariat of the National Plan on AIDS National Center of Epidemilogy Madrid, 24 November 26

2 Overview Background HIV epidemic in Spain Transmission patterns Overlap with HCV Unlinked Anonymous Testing (UAT) Methodology Results HIV prevalence Prevalence of HCV-HIV co-infection Conclusions

3 AIDS cases per million population in selected countries, , western Europe 2 Cases per million 15 Update 3 June Year of diagnosis Portugal Spain Italy France United Kingdom Germany EuroHIV

4 New annual AIDS cases by transmission category, adjusted for reporting delay. National AIDS Register. Updated June 3th, IDU Homosexual Heterosexual * 24* 25*

5 AIDS cases diagnosed in 25, by sex and transmission category. National AIDS Register. Updated June 3th, 26 Trans/hem,3% Hetero. 23,9% MTCT,2% Hetero. 53,9% MTCT 1,2% Homosex. 19,8% Otros/desc 5,1% Other 7,8% Men (n = 1134) IDU 5,7% Trans/Hem,3% IDU 36,8% Women (n = 345)

6 New HIV diagnosis by transmission category Data from 7 AARR (21-24) Casos IDU Hetero MSM MTCT Data: Canary Islands, Catalonia,Ceuta, Navarra, Basque Country, Extremadura and La Rioja

7 9 8 No. of AIDS cases due to mother-to-child transmission, adjusted by reporting delay National AIDS Register. Update at June 3th, 26 HAART Inhibidores de la proteasa Cases * 24* 25*

8 Natural History of HCV infection FREE OF DISEASE PRIMOINFECTION 2-5% CLEARANCE 5-8% CRONIC HEPATITIS CIRRHOSIS 2% ACUTE HEPATITIS 8% Asyntomatic HEPATOCELULAR CARCINOMA 1,5% TIME

9 Hospital Discharge Diagnosis among deceased HIV/AIDS patients, Porcentaje sobre el total de fallecidos en cada año ,8 3,4 34,8 4,7 7,5 4,7 68,5 62,1 6,5 41,9 5,8 52, HIV-related AIDS indicative Disease Other χ2 test for trend: p<.5 Source: CMBD ( )

10 Hospitalisations (N, %) due to viral hepatitis among HIV/AIDS patients, N(%) N(%) N(%) N(%) Hepatitis C* (17,6) (21,) (24,6) (26,3) Hepatitis B 771 (3,6) 83 (4,) Other viral hepatitis 814 (4,1) 79 (4,) Hepatitis A 12 (,1) 12 (,1) 4 () 16 (,1) Hepatitis Delta (wth hep B) 14 (,1) 15 (,1) 2 (,1) 16 (,1) Hepatitis E 5 () 4 () 3 () 1 () Other 17 (,1) 14 (,1) 17 (,1) 6 (,1) A patient can have more than one diagnosis *p<.5 en χ2 test for trnd Source: CMBD

11 Hospitalisations (%) due to acute/chronic Hepatitis B or C among HIV/AIDS patients p<.5 Porcentaje p<.5 5 Acute Hep B Chronic Hep B Acute Hep C Chronic Hep C Hepatitis víricas A patient can have more than one diagnosis p: χ2 test for trnd Source: CMBD

12 To sum up... High HIV/AIDS incidence in Spain. Many years, highest in Western Europe Mature concentrated epidemic Intravenous drug users (IDU), most commonly represented transmission category, but epidemic pattern has changed recently IDUs also at high risk for HCV Need to prevent HIV and HCV MTCT Need to establish information systems to know HIV & HIV-HCV prevalence in general population

13 HIV Prev:,3% (3-7% co-infected with HCV) VIH HCV Prev HIV-HCV:?? VIH/VHC HCV Prev: 1,5-2,5% Distribution of HIV & HCV infection in the Spanish population Wordwide Prev HCV: 3% Source: WHO

14 Unlinked Anonimous Testing in newborn babies Epidemiological information system Iinitiated in 1998 Setting: 8 Autonomous Regions Residual dried blood spots samples from routine neonatal screening Unlinked for identifiers Tested anonymously for HIV. All HIVpositive samples tested for Anti- HVC

15 Methodology- Dried blood samples Type 1 Type 2

16 Objetives To estimate prevalence of HIV infection in mothers of newborn babies To estimate prevalence of HIV-HCV coinfection in mothers of newborn babies

17 UAT Results, 24 (7 AR) Blood Samples HIV(+) Anti-HCV in HIV(+) Autonomous Regions No. Tested HIV(+)/1 women (IC95%) Anti- HCV (n) Anti-HCV (%) (IC95%) Proportion HIV-HVC+ /HIV+ CANARY ISLANDS ,15 (1,31-3,32) 4,43(,12-1,1) 2, CASTILLE- LEON ,11 (,7-1,69) 8,41(,17-,8) 36,36 CASTILLE-LA MANCHA 6.981,86 (,32-1,87) GALICE MELILLA MURCIA C. VALENCIANA TOTAL ,7 (1,15-2,42 ),74 (,2-4,1 ),8 (,43-1,37 ) 1,81 (1,45-2,22 ) 1,5 (1,29-1,74) ,62 (,31-1,11),25 (,7-,63),37(,22-,58),38 (,27-,5) 37,93 36,36 21,69 26,47

18 Results. Period (5 AR) HIV HCV-HIV Autonomous Regions Number Tested Prev.HIV +/1 (IC95%) HCV + (n) Prev.HIV-HVC +/1 (IC95%) Proportion HIV-HVC+ /HIV+ CANARY ISLANDS 12, ( ) ( ) CASTILLE- LEON 16, ( ) 5.47 ( ) GALICE 125, ( ) 88.7 ( ) MELILLA 7, ( ) 1.13 (.-.75) MURCIA 11, ( ) ( ) TOTAL 444, ( ) ( ) 39.5 HIV + ( ): 618 HCV tested HVC: 562 (9,9%)

19 HIV(+) mothers. Proportion with Anti-HCV , 5 AARR Percentage , Year HIV + ( ): 618 HCV tested HVC: 562 (9,9%)

20 HIV(+) mothers. Proportion with Anti-HCV by Autonomous Regions Percentage Canary Islands Castille-Leon Galice Murcia Melilla HIV + ( ): 618 Tested HVC: 562 (9,9%)

21 Prevalence of de HIV and HIV-HCV co-infection per 1 women (5 AARR) 2 Prevalence/1 women 1,6 1,2,8, Year HIV/1. HIV-HCV/1. Chi- Square of tendency: NS

22 Prevalence of HIV and HIV-HCV co-infection per 1 women. Canary Islands 6 p<.5 2,5 Percentage ,5 1,5 Prevalence/1 women % COINFECTION HIV/1. HIV-HCV/1. Chi- Square of tendency prevalence HIV/HCV: NS

23 Prevalence of HIV and HIV-HCV co-infection per 1 women. Castille-Leon ,5 Percentage ,5 1,5 Prevalence/1 women % COINFECTION HIV/1. HIV-HCV/1. Chi- Square of tendency prevalence HIV/HCV and prevalence HIV: NS

24 Prevalence of HIV and HIV-HCV co-infection per 1 women. Galice 7 2,5 Percentage ,5 1,5 Prevalence/1 women % COINFECTION HIV/1. HIV-HCV/1. Chi- Square of tendency prevalence HIV/HCV and prevalence HIV: NS

25 Prevalence of HIV and HIV-HCV co-infection per 1 women. Murcia 6 1,8 Percentage ,6 1,4 1,2 1,8,6,4,2 Prevalence/1 women % COINFECTION HIV/1. HIV-HCV/1. Chi- Square of tendency prevalence HIV/HCV and prevalence HIV: NS

26 Conclusions UAT using residual dried blood spots samples from routine neonatal screening is feasible and costeffective It provides important information on HIV infection and HCV-HIV co-infection trends, in unselected group of the Spanish population Prevalence of HIV-ACV is high in comparison with other European countries, and stable during HCV testing should always be done in HIV(+) pregnant women, as well as in all those with risk factors for HCV infection Challenges: a) extend the program to other AARR; b) add some important epidemiological variables